Patel's jaunty and amusing article concludes with: "after all, how bad can man flu be?" 1 The answer is that, for men and women, flu can be devastating and even lethal. This is especially true for sick and vulnerable patients. Patel misses the point: we should be vaccinated not only to keep us hard at work through those long winter days and nights, but also to prevent us getting flu and, despite feeling lousy, struggling in to work and infecting our patients. Doctors cannot rely on recollection of symptoms to know whether they have been infected or are protected against flu.
2
In our study of 1520 patients with flu in 75 different NHS hospitals during the 2009 pandemic, we identified 30 cases of probable hospital acquired infection. Of these, 26 had serious underlying illnesses. Only 12 were treated with appropriate antiviral drugs within 48 hours of onset, more than half needed escalated care, and eight died.
3 Although we do not know how many were infected by hospital staff, these findings clearly support this autumn's campaign to boost our patchy record on healthcare worker vaccination.
The arguments are not only scientific but moral. We all know that a precept of medical ethics is "first, do no harm," and the General Medical Council clearly advises us to conduct ourselves in a manner that minimises the harm we do to those in our care. 4 Patel is wrong to focus on his personal freedom, seeming to ignore the potential consequences of his choices on the health and survival of his patients.
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